celecoxib has been researched along with sulfasalazine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A | 1 |
| Wasko, MC; Wildy, KS | 1 |
| Aranda, CP; Cassai, N; Mehandru, S; Sidhu, GS; Smith, RL | 1 |
| Kandefer-Szerszeń, M; Majdan, M; Parada-Turska, J; Rzeski, W; Turski, WA | 1 |
| Jo, SJ; Park, JY; Yoon, HS; Youn, JI | 1 |
| Winfield, LL; Yerokun, T | 1 |
| Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ | 1 |
| Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ | 1 |
| Wang, Y; Xiao, X | 1 |
2 review(s) available for celecoxib and sulfasalazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Methotrexate; Osteoarthritis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfasalazine; Sulfonamides; Sulfones | 2001 |
1 trial(s) available for celecoxib and sulfasalazine
| Article | Year |
|---|---|
Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial.
Topics: Celecoxib; Drugs, Chinese Herbal; Female; Humans; Male; Spondylitis, Ankylosing; Sulfasalazine; Treatment Outcome | 2018 |
14 other study(ies) available for celecoxib and sulfasalazine
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles | 2019 |
Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.
Topics: Aged; Airway Obstruction; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Male; Pulmonary Fibrosis; Pyrazoles; Radiography; Sulfasalazine; Sulfonamides | 2002 |
Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro.
Topics: Animals; Antirheumatic Agents; Benzodiazepines; Benzodiazepinones; Celecoxib; Cell Line; Cell Proliferation; Cell Survival; Diclofenac; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Inhibitory Concentration 50; Methotrexate; Naproxen; Pyrazoles; Quinoxalines; Sulfasalazine; Sulfonamides; Synovial Membrane | 2006 |
Case of acrodermatitis continua accompanied by psoriatic arthritis.
Topics: Acrodermatitis; Administration, Cutaneous; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Calcitriol; Celecoxib; Dermatologic Agents; Diagnosis, Differential; Humans; Male; Pyrazoles; Radiography; Sulfasalazine; Sulfonamides | 2006 |
Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2 Inhibitors; Drug Screening Assays, Antitumor; Drug Synergism; Glioma; Humans; Sulfasalazine; Sulfonamides | 2015 |
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Case-Control Studies; Celecoxib; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Humans; Hyperlipidemias; Hypertension; Middle Aged; Odds Ratio; Protective Factors; Spondylitis, Ankylosing; Sulfasalazine; Taiwan | 2016 |
Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Chi-Square Distribution; Databases, Factual; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Protective Factors; Retrospective Studies; Risk Factors; Spondylitis, Ankylosing; Sulfasalazine; Taiwan; Time Factors; Treatment Outcome; Young Adult | 2017 |